JAMS to Resolve Cases in HISA’s Anti-Doping Program

JAMS, the largest private provider of alternative dispute resolution (ADR) services worldwide, will strengthen the integrity of United States horseracing by hearing cases under the newly created Horseracing Integrity and Safety Authority's (HISA) Anti-Doping and Medication Control (ADMC) Program.

The industry-first program, administered by the Horseracing Integrity & Welfare Unit (HIWU), seeks to establish nationwide, uniform and efficient results management and adjudication processes for Anti-Doping and Controlled Medication Rule Violations. The Program will create a centralized testing and results management process and apply uniform penalties for violations across all American Thoroughbred racing jurisdictions that HISA governs, beginning March 27, 2023

As the arbitral body appointed by HISA and HIWU, JAMS will maintain a panel of arbitrators to administer and hear Anti-Doping Rule Violation cases. The panel will consist of neutrals, many of whom have experience in anti-doping and/or sports adjudication. As part of its role, JAMS will provide procedural fairness to the parties involved.

"We are pleased to support the rollout of this program, which will help ensure neutrality and consistency in the enforcement of one part of the rules that govern horseracing. We believe the administrative excellence of the JAMS organization, and the quality and deep experience of our arbitrators, will be invaluable in resolving cases brought by HIWU. We are proud to do our part in a program that will help maintain the integrity of the sport."- John Pardun, vice president of JAMS Solutions

HIWU was established in 2022 by Drug Free Sport International to administer the rules and enforcement mechanisms of HISA's ADMC Program. HISA was established by the Horseracing Integrity and Safety Act of 2020. Under the act, HISA submitted the Equine Anti-Doping and Controlled Medication Protocol (under Rule Series 3000) and the Arbitration Procedures (under Rule Series 7000) to the Federal Trade Commission (FTC), which will become effective March 27, 2023 (pending approval by the FTC). As established by the Equine Anti-Doping and Controlled Medication Protocol (under Rule Series 3000) and the Arbitration Procedures (under Rule Series 7000), JAMS will fulfill certain requirements described therein of the arbitral body to resolve alleged Anti-Doping Violations. More information about the rules update can be found here.